Wellgistics Health (WGRX) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the WGRX SEC filings page.
Wellgistics Health, Inc. (WGRX) reported $14.0M in revenue over the twelve months to Mar 31, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue grew, but direct costs and overhead expanded faster, turning a modest operating business into a heavily loss-making, financing-dependent operation.
Revenue increased28.7% in FY2025, yet gross margin fell 37.3 percentage points, showing that additional sales worsened rather than improved the economics of each sale. Operating cash flow deteriorated from-$1.2M to-$10.9M as overhead expanded dramatically, so growth increased cash demands instead of funding growth.
FY2025 ended with liabilities of
Financing cash inflow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Wellgistics Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Wellgistics Health, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 13/100.
Wellgistics Health, Inc.'s revenue surged 28.7% year-over-year to $23.3M, reflecting rapid business expansion. This strong growth earns a score of 88/100.
Wellgistics Health, Inc.'s current ratio of 0.09 is below the typical benchmark, resulting in a score of 1/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Not available for Wellgistics Health, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Wellgistics Health, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Wellgistics Health, Inc. reported a net loss of $101.3M while operations used $10.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Wellgistics Health, Inc. reported an operating loss of $93.7M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Wellgistics Health, Inc. generated $1.6M in revenue in Q1 2026. This represents a decrease of 85.6% from the same quarter a year earlier. Against the prior quarter it is down 6.6%.
Wellgistics Health, Inc.'s EBITDA was -$5.7M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Wellgistics Health, Inc. reported a net loss of $7.7M in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Wellgistics Health, Inc. held $52K in cash against $12.6M in long-term debt as of Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Wellgistics Health, Inc.'s gross margin was 10.9% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is up 4.5 percentage points from the same quarter a year earlier.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q1 2026.
Capital Allocation
None of these metrics is reported for Q1 2026.
WGRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M-85.6% | $1.7M | $3.0M-46.9% | $7.8M+17391.8% | $10.9M | N/A | $5.7M | $45K |
| Cost of Revenue | $1.4M-86.3% | $9.5M | $2.8M-46.0% | $7.3M+15351.6% | $10.2M | N/A | $5.2M | $47K |
| Gross Profit | $170K-75.4% | -$7.9M | $231K-55.7% | $506Kn/m | $693K | N/A | $521K | -$3K |
| SG&A Expenses | $4.9M-84.4% | $4.1M | $30.2M+1577.5% | $4.9M+752.0% | $31.2M+38981.4% | N/A | $1.8M | $570K |
| Operating Income | -$6.0Mn/m | -$25.4M | -$31.5Mn/m | -$5.5Mn/m | -$31.3Mn/m | N/A | -$1.7M | -$573K |
| EBITDA | -$5.7Mn/m | -$24.5M | -$30.7Mn/m | -$4.7Mn/m | -$30.5M | N/A | -$1.3M | -$573K |
| Interest Expense | $2.1M+89.4% | $876K | $1.4M+935.7% | $1.2M+90353.8% | $1.1M+32493.5% | N/A | $138K | $1K |
| Net Income | -$7.7Mn/m | -$27.9M | -$34.3Mn/m | -$6.7Mn/m | -$32.4Mn/m | N/A | -$1.9M | -$574K |
| EPS (Basic) | -$0.07 | N/A | -$0.46 | -$0.11n/m | -$0.62n/m | N/A | -$0.04 | -$0.01 |
| EPS (Diluted) | -$0.07 | N/A | -$0.46 | -$0.11n/m | -$0.62n/m | N/A | -$0.04 | -$0.01 |
| Diluted Shares (Avg) | 105M | N/A | 74M | 62M+34.6% | 52M+16.1% | N/A | 48M | 46M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
WGRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.1M-48.1% | $30.5M-46.9% | $52.8M | $54.2M | $58.1M | $57.3M+16844.1% | N/A | N/A |
| Current Assets | $2.8M-83.3% | $2.8M-81.4% | $12.8M | $13.5M | $16.6M | $15.2M+4382.9% | N/A | N/A |
| Cash & Equivalents | $52K-97.9% | $43K-95.9% | $4.2M | $420K | $2.5M | $1.0M+75291.2% | N/A | N/A |
| Inventory | $1.7M-82.4% | $1.6M-82.8% | $7.5M | $9.0M | $9.7M | $9.5M | N/A | N/A |
| Accounts Receivable | $992K-64.9% | $1.1M-58.3% | $1.1M | $2.2M | $2.8M | $2.7M | N/A | N/A |
| Goodwill | $14.2M-12.5% | $14.2M-12.5% | $16.2M | $16.2M | $16.2M | $16.2M | N/A | N/A |
| Total Liabilities | $45.2M-15.7% | $42.9M-15.2% | $46.0M | $53.3M | $53.6M | $50.6M+1462.3% | N/A | N/A |
| Current Liabilities | $32.2M-30.3% | $29.8M-21.7% | $32.7M | $42.4M | $46.2M | $38.0M+1217.0% | N/A | N/A |
| Non-Current Liabilities | $13.0M+76.5% | $13.1M+4.6% | $13.3M | $10.9M | $7.4M | $12.6M+3486.1% | N/A | N/A |
| Long-Term Debt | $12.6M-47.8% | $12.6M+10.0% | $12.6M | $10.1M | $24.1M | $11.5M | N/A | N/A |
| Total Equity | -$15.1M-436.3% | -$12.4M-284.8% | $6.8M-32.1% | $905Kn/m | $4.5Mn/m | $6.7Mn/m | $10.0M | -$3.1M |
| Retained Earnings | -$118.8Mn/m | -$111.0Mn/m | -$83.2M | -$48.9M | -$42.2M | -$9.8Mn/m | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
WGRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.4Mn/m | -$6.3Mn/m | -$1.1M-209.4% | -$2.1M-730.1% | -$1.3M-4413.6% | -$2.6M | $1.0M | $330K |
| Depreciation & Amortization | $357K-55.6% | $803K | $803K+71.7% | $803Kn/m | $803K | N/A | $467K | $0 |
| Stock-Based Compensation | $1.4M-95.1% | N/A | $25.7M | $935K | $27.8M | N/A | N/A | N/A |
| Investing Cash Flow | -$205Kn/m | -$255K-131.8% | -$221Kn/m | -$132K | -$273K | $803K | -$316K | N/A |
| Financing Cash Flow | $3.6M+16.7% | $2.4M+14.9% | $5.2M+114198.3% | $114Kn/m | $3.1M+1095.7% | $2.1M | $5K | -$538K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
WGRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 10.9%+4.5pp | -470.2% | 7.7%-1.5pp | 6.5%+12.3pp | 6.4% | N/A | 9.2% | -5.9% |
| Operating Margin | -385.7% | -1517.5% | -1047.1% | -70.6% | -288.6% | N/A | -30.8% | -1286.5% |
| Net Margin | -496.5% | -1667.2% | -1139.0% | -85.6% | -298.5% | N/A | -32.9% | -1289.5% |
| Return on Equity | N/A | N/A | -506.3%-487.6pp | -737.1% | -724.1% | N/A | -18.7% | N/A |
| Return on Assets | -25.7%+30.1pp | -91.4% | -65.0% | -12.3% | -55.9% | N/A | N/A | N/A |
| Current Ratio | 0.09-0.3x | 0.09-0.3x | 0.39 | 0.32 | 0.36 | 0.40+0.3x | N/A | N/A |
| Debt-to-Equity | N/A | N/A | 1.86 | 11.16 | 5.39 | 1.70 | N/A | N/A |
| Liabilities-to-Equity | N/A | N/A | 6.79 | 58.90 | 11.96 | 7.51 | N/A | N/A |
| Asset Turnover | 0.05-0.1x | 0.05 | 0.06 | 0.14 | 0.19 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$12.4M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Wellgistics Health, Inc. WGRX | FY2025 | $23.3M | -$101.3M | N/A | N/A | 29/100 |
| PetMed Express, Inc. PETS | FY2026 | $179.0M | -$57.3M | -32.0% | $25.6M | 41/100 |
| High Tide Inc. HITI | FY2025 | $424.0M | -$36.2M | -8.5% | $238.0M | 49/100 |
| Scienture Holdings, Inc. SCNX | FY2025 | $432K | -$41.5M | N/A | $5.3M | — |
| Cellyan Biotechnology Co., Ltd HKPD | FY2026 | $13.4M | -$1.1M | -8.5% | $5.3M | 44/100 |
Where Wellgistics Health, Inc. Ranks
Frequently Asked Questions
What is Wellgistics Health, Inc.'s annual revenue?
Wellgistics Health, Inc. (WGRX) reported $23.3M in total revenue for fiscal year 2025. This represents a 28.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Wellgistics Health, Inc.'s revenue growing?
Wellgistics Health, Inc. (WGRX) revenue grew by 28.7% year-over-year, from $18.1M to $23.3M in fiscal year 2025.
Is Wellgistics Health, Inc. profitable?
No, Wellgistics Health, Inc. (WGRX) reported a net loss of $76.6M over the trailing 12 months to March 31, 2026. In fiscal year 2025 it reported a net loss of $101.3M.
What is Wellgistics Health, Inc.'s EBITDA?
Wellgistics Health, Inc. (WGRX) had EBITDA of -$90.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Wellgistics Health, Inc. have?
As of fiscal year 2025, Wellgistics Health, Inc. (WGRX) had $43K in cash and equivalents against $12.6M in long-term debt.
What is Wellgistics Health, Inc.'s gross margin?
Wellgistics Health, Inc. (WGRX) had a gross margin of -27.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Wellgistics Health, Inc.'s operating cash flow?
Wellgistics Health, Inc. (WGRX) recorded an outflow of $10.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Wellgistics Health, Inc.'s total assets?
Wellgistics Health, Inc. (WGRX) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Wellgistics Health, Inc.'s current ratio?
Wellgistics Health, Inc. (WGRX) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Wellgistics Health, Inc.'s return on assets (ROA)?
Wellgistics Health, Inc. (WGRX) had a return on assets of -332.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Wellgistics Health, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Wellgistics Health, Inc. (WGRX) held $43K in cash, cash equivalents and investments, and reported an operating cash outflow of $10.9M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Wellgistics Health, Inc.'s debt-to-equity ratio negative or not reported?
Wellgistics Health, Inc. (WGRX) has negative shareholder equity of -$12.4M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Wellgistics Health, Inc.'s Piotroski F-Score?
Wellgistics Health, Inc. (WGRX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Wellgistics Health, Inc.'s earnings high quality?
Wellgistics Health, Inc. (WGRX) reported a net loss of $101.3M while operations used $10.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Wellgistics Health, Inc. cover its interest payments?
Wellgistics Health, Inc. (WGRX) reported an operating loss of $93.7M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Wellgistics Health, Inc.?
Wellgistics Health, Inc. (WGRX) scores 29 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Wellgistics Health, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.